Effects of Lenvatinib combined with immune checkpoint inhibitors on efficacy, immune function and prognosis in patients with primary liver cancer

医学 伦瓦提尼 免疫系统 癌症研究 肝癌 肿瘤科 免疫检查点 功能(生物学) 无容量 癌症 肝功能 免疫学 免疫疗法 内科学 CTLA-4号机组 不利影响 程序性细胞死亡1
作者
Yuehong Hou,Zhenlin Gao,Ci Liu,Yajing Zhang,Dongliang Zhang
出处
期刊:Pakistan Journal of Medical Sciences [Professional Medical Publications]
卷期号:41 (12): 3379-3384
标识
DOI:10.12669/pjms.41.12.12763
摘要

Objective: To evaluate the clinical efficacy, immune function effects and safety of lenvatinib combined with immune checkpoint inhibitors (sintilimab) in treating advanced primary liver cancer. Methodology: A retrospective cohort study was conducted on 80 patients with advanced liver cancer in Shijiazhuang People’s Hospital from January 2023 to June 2024, who were divided into an observation group (lenvatinib + sintilimab, n=40) and a control group (lenvatinib monotherapy, n=40). Specifically, the overall response rate (ORR), immune function indicators (CD3+, CD4+, CD4+/CD8+, IgM/IgG/IgA), quality of life (SGRQ scores) and adverse reactions were compared between the two groups. Results: The ORR in the observation group (72.5%) was significantly higher than that in the control group (50.0%), with statistically significant differences (P=0.039). After treatment, the improvement in levels of CD3+, CD4+, CD4+/CD8+ and immunoglobulins (IgM, IgG, IgA) in the observation group significantly outperformed those in the control group, with statistically significant differences (all P<0.05). Additionally, the observation group reported more substantially improved SGRQ scores than the control group and differences were statistically significant (P<0.001). In terms of safety, no statistical differences were observed regarding the incidence of adverse reactions in both groups (P=0.369). Conclusion: Lenvatinib combined with immune checkpoint inhibitors can significantly improve the objective response rate in patients with advanced liver cancer, enhance their immune function and improve their quality of life, demonstrating satisfactory safety.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
orixero的应助被wyc采纳,获得10
刚刚
刚刚
1秒前
2秒前
2秒前
小览群书完成签到 ,获得积分10
3秒前
核桃发布了新的文献求助10
3秒前
灞波儿奔的应助被kinji采纳,获得10
3秒前
cc发布了新的文献求助10
4秒前
Easonluo8完成签到,获得积分10
4秒前
yutian完成签到,获得积分20
4秒前
韩小青发布了新的文献求助10
4秒前
霜之哀伤完成签到,获得积分10
4秒前
4秒前
4秒前
5秒前
蟹寒樂发布了新的文献求助10
6秒前
6秒前
can发布了新的文献求助10
6秒前
6秒前
合适的白筠完成签到,获得积分10
7秒前
搜集达人的应助被去向未来采纳,获得20
7秒前
8秒前
8秒前
llll发布了新的文献求助10
8秒前
9秒前
10秒前
888发布了新的文献求助10
10秒前
211完成签到,获得积分20
11秒前
SciGPT的应助被小周爱学术采纳,获得10
12秒前
13秒前
石头完成签到,获得积分10
13秒前
TUOUO完成签到,获得积分10
13秒前
无所事事完成签到,获得积分10
14秒前
wyc发布了新的文献求助10
14秒前
unforgettable发布了新的文献求助10
14秒前
14秒前
zyl666关注了科研通微信公众号
14秒前
15秒前
王永明完成签到,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183894
求助须知:如何正确求助?哪些是违规求助? 9573067
关于积分的说明 21829226
捐赠科研通 7780983
什么是DOI,文献DOI怎么找? 3434150
关于科研通互助平台的介绍 2558315
邀请新用户注册赠送积分活动 2480648